Cocaine as a risk factor for neuroleptic-induced acute dystonia

J Clin Psychiatry. 1998 Mar;59(3):128-30. doi: 10.4088/jcp.v59n0307.

Abstract

Background: A prospective study was conducted to test the hypothesis that cocaine use is a risk factor for neuroleptic-induced acute dystonia (NIAD).

Method: The study sample consisted of a high-risk group for NIAD, males aged 17-45 years who had received high-potency neuroleptics within 24 hours of admission and had not used neuroleptics in the month prior to admission. Patients were excluded if they suffered from a neurodegenerative disorder or were exposed to anticholinergics, benzodiazepines, promethazine, carbamazepine, phenytoin, or levodopa during the study. Twenty-nine patients--9 cocaine users and 20 nonusers--entered the study, which lasted 2 years. Patients were followed for 7 days.

Results: Cocaine-using psychiatric patients developed significantly more NIAD than did nonusers (relative risk = 4.4, 95% CI = 1.4 to 13.9).

Conclusion: Cocaine use is a major risk factor for NIAD and should be added to the list of well-known risk factors. The authors strongly suggest that cocaine-using psychiatric patients who are started on a regimen of neuroleptics should also be administered an anticholinergic for at least 7 days to prevent NIAD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antipsychotic Agents / adverse effects*
  • Antipsychotic Agents / therapeutic use
  • Bipolar Disorder / drug therapy
  • Bipolar Disorder / epidemiology
  • Cholinergic Antagonists / therapeutic use
  • Cocaine-Related Disorders / epidemiology*
  • Comorbidity
  • Drug Therapy, Combination
  • Dystonia / chemically induced*
  • Dystonia / epidemiology
  • Dystonia / prevention & control
  • Humans
  • Male
  • Middle Aged
  • Netherlands Antilles / epidemiology
  • Prospective Studies
  • Psychotic Disorders / drug therapy*
  • Psychotic Disorders / epidemiology
  • Risk Factors
  • Schizophrenia / drug therapy
  • Schizophrenia / epidemiology

Substances

  • Antipsychotic Agents
  • Cholinergic Antagonists